Compare Revvity Inc (RVTY) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs ProShares UltraPro S&P500 — how do they compare? Revvity Inc trades at $154.18 (market cap $16.98B), while ProShares UltraPro S&P500 trades at $155.73 (market cap $5.55B). The key difference: Revvity Inc is far larger — about 3.1× ProShares UltraPro S&P500's market cap, and Revvity Inc pays a 0.18% dividend while ProShares UltraPro S&P500 pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and ProShares UltraPro S&P500 for 29 Days on average.
| RVTY | UPRO | |
|---|---|---|
Market Cap | $16.98B | $5.55B |
Volume | 1,456,900 | 2,078,694 |
Sector | Health | Leveraged / Inverse |
52-Week High | $157.36 | $157.66 |
52-Week Low | $82.26 | $89.29 |
Typical Hold Time | 12 Days | 29 Days |
Enterprise Value | $19.30B | — |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.
The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.
UPRO trades at $155.73, up 0.34% today, with a bullish technical signal from moving averages and neutral oscillators. The stock faces resistance near $157 and support at $151. Key financial ratios are not available in the provided data, limiting fundamental assessment. A dividend of $0.27 is scheduled for September 2026.
The outlook is cautiously optimistic due to bullish technical trends, but the absence of fundamental metrics like P/E and ROE increases reliance on market sentiment. Risks include S&P 500 volatility and profit growth concerns highlighted in recent news. Investors should seek updated financials for a complete view.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
